DaVita ROE 2010-2024 | DVA
Current and historical return on equity (ROE) values for DaVita (DVA) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| DaVita ROE - Return on Equity Historical Data |
| Date |
TTM Net Income |
Shareholder's Equity |
Return on Equity |
| 2024-12-31 |
$0.94B |
$0.40B |
126.37% |
| 2024-09-30 |
$0.83B |
$0.59B |
86.94% |
| 2024-06-30 |
$0.86B |
$0.85B |
74.77% |
| 2024-03-31 |
$0.82B |
$1.13B |
65.86% |
| 2023-12-31 |
$0.69B |
$1.24B |
57.17% |
| 2023-09-30 |
$0.61B |
$1.38B |
54.45% |
| 2023-06-30 |
$0.47B |
$1.21B |
49.21% |
| 2023-03-31 |
$0.51B |
$1.02B |
60.95% |
| 2022-12-31 |
$0.56B |
$0.88B |
66.45% |
| 2022-09-30 |
$0.68B |
$0.70B |
79.16% |
| 2022-06-30 |
$0.83B |
$0.78B |
82.23% |
| 2022-03-31 |
$0.90B |
$1.02B |
76.12% |
| 2021-12-31 |
$0.98B |
$0.94B |
75.81% |
| 2021-09-30 |
$0.97B |
$1.33B |
66.66% |
| 2021-06-30 |
$0.86B |
$1.46B |
55.60% |
| 2021-03-31 |
$0.77B |
$1.43B |
43.57% |
| 2020-12-31 |
$0.78B |
$1.57B |
39.81% |
| 2020-09-30 |
$0.85B |
$1.75B |
39.63% |
| 2020-06-30 |
$0.83B |
$2.33B |
35.70% |
| 2020-03-31 |
$0.90B |
$2.13B |
32.19% |
| 2019-12-31 |
$0.81B |
$2.32B |
24.65% |
| 2019-09-30 |
$0.42B |
$2.51B |
11.28% |
| 2019-06-30 |
$0.14B |
$4.24B |
3.34% |
| 2019-03-31 |
$0.13B |
$4.09B |
3.13% |
| 2018-12-31 |
$0.16B |
$3.91B |
3.70% |
| 2018-09-30 |
$0.61B |
$4.03B |
13.46% |
| 2018-06-30 |
$0.54B |
$4.49B |
11.19% |
| 2018-03-31 |
$0.40B |
$4.78B |
7.94% |
| 2017-12-31 |
$0.66B |
$4.89B |
12.98% |
| 2017-09-30 |
$0.52B |
$4.97B |
10.16% |
| 2017-06-30 |
$1.30B |
$5.27B |
25.34% |
| 2017-03-31 |
$1.23B |
$5.34B |
24.27% |
| 2016-12-31 |
$0.88B |
$4.85B |
17.71% |
| 2016-09-30 |
$0.72B |
$5.12B |
14.24% |
| 2016-06-30 |
$0.36B |
$4.96B |
7.14% |
| 2016-03-31 |
$0.48B |
$4.92B |
9.29% |
| 2015-12-31 |
$0.27B |
$5.08B |
5.17% |
| 2015-09-30 |
$0.48B |
$5.19B |
9.17% |
| 2015-06-30 |
$0.45B |
$5.35B |
8.58% |
| 2015-03-31 |
$0.43B |
$5.17B |
8.31% |
| 2014-12-31 |
$0.72B |
$5.36B |
14.24% |
| 2014-09-30 |
$0.73B |
$5.15B |
14.87% |
| 2014-06-30 |
$0.68B |
$4.96B |
14.44% |
| 2014-03-31 |
$0.79B |
$4.84B |
17.31% |
| 2013-12-31 |
$0.63B |
$4.61B |
14.65% |
| 2013-09-30 |
$0.58B |
$4.44B |
13.91% |
| 2013-06-30 |
$0.59B |
$4.28B |
15.78% |
| 2013-03-31 |
$0.43B |
$3.96B |
13.06% |
| 2012-12-31 |
$0.54B |
$3.92B |
18.65% |
| 2012-09-30 |
$0.53B |
$2.67B |
21.45% |
| 2012-06-30 |
$0.52B |
$2.51B |
22.38% |
| 2012-03-31 |
$0.52B |
$2.40B |
24.05% |
| 2011-12-31 |
$0.48B |
$2.27B |
22.67% |
| 2011-09-30 |
$0.40B |
$2.08B |
19.46% |
| 2011-06-30 |
$0.38B |
$1.95B |
18.03% |
| 2011-03-31 |
$0.39B |
$2.14B |
17.56% |
| 2010-12-31 |
$0.41B |
$2.04B |
17.82% |
| 2010-09-30 |
$0.45B |
$2.38B |
19.29% |
| 2010-06-30 |
$0.44B |
$2.36B |
19.45% |
| 2010-03-31 |
$0.44B |
$2.32B |
20.03% |
| 2009-12-31 |
$0.42B |
$2.19B |
20.36% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$11.363B |
$12.816B |
|
DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services. DaVita's Dialysis and related lab services business segment provides inpatient as well as outpatient dialysis services, routine laboratory testing for ESRD patients and management services to outpatient dialysis centers. The company's other ancillary services and strategic initiatives segment includes its international dialysis services, pharmacy services, infusion therapy services, disease management services, vascular access services, ESRD clinical research programs and physician services.
|
